Creso Pharma Canadian subsidiary ramps up cannabis production ahead of premium retail product launch

Creso Pharma Limiteds (ASX:CPH) (FRA:1X8) Canadian subsidiary Mernova Medicinal Inc is ramping up cannabis production towards maximum capacity ahead of the launch of its premium retail products.

Mernova, a licensed producer in Nova Scotia, Canada, has been focusing on streamlining its operations to meet growing demand from medical and recreational markets in Canada after it received its sales licence from Health Canada in May.

These optimisation changes have streamlined production and delivered tangible improvements to cannabis quality, with increased yields expected over the coming months.

Initial offerings[hhmc]

Mernovas high-quality initial offerings will be dried flower in its natural form, with other new premium products such as extracts and pre-rolled joints soon to follow.

Mernova has also initiated several proprietary processes to enhance product quality to meet growing demand for small-batch, artisanal cannabis products in Canada.

The improvements have recently been made to Mernovas post-harvest processes and are already having positive effects on the aroma, appearance, feel and overall quality of the cannabis.

In talks with several parties[hhmc]

Creso said it was in discussions with several parties in North America over the sale of its high-quality dried flower and cannabis 2.0 products and will update on further progress when possible.

Creso Pharma chief executive officer and co-founder Dr Miri Halperin Wernli said: “Mernova has been busy setting the stage for its retail product launch and we are delighted with the level of activity achieved over the past few months, even amidst the backdrop of challenging global conditions.

“Alongside the streamlining of operations, discussions are also underway with a number of potential customers in the Canadian market and we look forward to updating shareholders on developments when appropriate.”

Seeking high-quality product[hhmc]

Mernova managing director Jack Yu said: “Early in our planning, we identified that the premium market is looking for high-quality cannabis, specifically indoor grown, small-batch, artisanal product that isnt grown under the same factory processes used by a number of the large-scale cannabis producers.

“We saw this as a massive near-term opportunity for Mernova andRead More – Source

[contf]
[contfnew]

Proactiveinvestors

[contfnewc]
[contfnewc]